

2022 Initial Public Offering Healthcare Industry is in the Spotlight




From its briefing on the result of the first half of 2022, HKEX has pointed out that the proceeds from initial public offering in the first half of the year reached to HK\$19.7 billion (a decrease of 91% year-on-year), of which 81% came from new economy and biotech companies. Among these, Zai Lab has become the first company in Main Board to complete its conversion from secondary listing to primary listing. Even though being affected by the sentiment of global market, the new stock market remains a strong momentum in receiving listing applications. As of 30 June 2022, more than 180 applications are being processed, including 11 SPAC applications. What's more, there are 16 newly listing companies on July 2022, showing a sign of recovery in the new stock market.

Nicolas AGUZIN, the CEO of HKEX, gave a speech on the fifth Biotech Summit on 1 September 2022, mentioning that the implementation of the 2018 listing reforms has successfully attracted nearly 100 biotech and healthcare listings to HKEX's Main Board, raising close to HK\$260 billion, representing a fifth of global IPO raising in the sector between 2018 and the end of 2021.

The CEO of HKEX Nicolas AGUZIN added:

We will continue to diversify our markets and cater to the funding needs of other large-scale advanced technologies companies which are at an early stage of product commercialisation, including healthcare companies.




RemeGen also indicated that it has gained a huge boost after listing in Hong Kong. Jianmin Fang, Co-Founder, CEO and CSO of RemeGen said:

Listing in Hong Kong helped support our research and development, and it also helped us go global by raising our profile and connecting our company with opportunities overseas.

Cheong Man Lei Lillian, the Deputy Secretary for Innovation, Technology and Industry Bureau of the government of Hong Kong, also highlighted on her speech that research clusters and projects would spring up in Hong Kong with support from government policies, HKEX's listing reforms, rich talent pools and Hong Kong's world-renowned status as an IFC. Looking forward, with innovation taking centre stage and with further reforms in the pipeline, there are significant opportunities to attract an even more diverse range of healthcare and life science companies to Hong Kong and HKEX's markets, strengthening the city's role as a leading biotech hub.

Source :

https://www.hkex.com.hk/-/media/HKEX-Market/News/News-Release/2022/220817news/2022Interim-Media-PPT_c.pdf
<https://www.hkexgroup.com/media-centre/insight/insight/2022/hkex/biotech-summit-2022-advancing-towards-the-healthcare-of-tomorrow?>



ProTop

Founded by a group of industry's veterans, ProTop has over 20 years' experiences in handling various types of financial documents and provides diversifying financial document printing and logistics management services. We have production centers in both Hong Kong and Shenzhen. With professional and quality services, we enjoy good reputation in the market.

2022 Copyrights ProTop Financial Press Limited

Contact us

Email: marketing@protop.com.hk / Website: www.protop.com.hk

Follow us



If you do not wish to receive this email, please [press here](#).

Disclaimer

This notice is for information purposes only and does not constitute an offer, or confirmation or commitment to conclude a covenant or transaction. ProTop Financial Press Limited does not guarantee the completeness and correctness of data or other information contained in this notice. Such data or information would be changed at any time without prior notice, while the comment or statement in this notice should not be treated as comment or opinion of ProTop Financial Press Limited or its associated companies. Information from internet may contain virus, the recipient should confirm the safety of this mail by his/her own. ProTop Financial Press Limited does not assume any liability for any loss incurred.